Pfizer’s PFE non-COVID operational revenues improved in the first three quarters of 2024, driven by its key in-line products ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Health experts are seeing signs of a much smaller wave of U.S. COVID-19 cases this winter than in previous years, which could ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.

Pfizer (NYSE:PFE – Get Free Report) had its price objective decreased by equities research analysts at Citigroup from $30.00 ...

Drugmakers raised the list prices of more than 800 prescription drugs for blood pressure, cancer and other conditions by a ...

PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the ...

Shares of Pfizer Inc. (NYSE:PFE – Get Free Report) have been given a consensus rating of “Moderate Buy” by the sixteen ...

Dividend stocks can be a great way to boost your portfolio's growth potential or provide a form of passive income over the ...

Some stocks pay juicy dividends for a while only for the income to later dwindle. Others generate consistent and reliable ...